ELISE TETELMAN: Open Payments
NPI 1225530686 · SAN DIEGO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,630 in 108 payments from 30 companies in 2025. Trend: 2023 $218 · 2024 $583 · 2025 $4,630
Food & beverage: $4,630
| Company | Payments | Amount |
|---|---|---|
| Incyte Corporation | 11 | $533 |
| Regeneron Healthcare Solutions, Inc. | 3 | $369 |
| CSL Behring | 8 | $360 |
| AstraZeneca Pharmaceuticals LP | 4 | $277 |
| Grifols USA, LLC | 5 | $267 |
| Novartis Pharmaceuticals Corporation | 9 | $262 |
| ARS Pharmaceuticals Operations, Inc. | 6 | $224 |
| Amgen Inc. | 4 | $198 |
| GlaxoSmithKline, LLC. | 6 | $197 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $192 |
Products named: DUPIXENT, OPZELURA, Xembify, NEFFY, AYVAKIT, NEMLUVIO, NUCALA, Hizentra.
Industry payments across CA — which companies pay providers there.
